Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New target for skin cancer confirmed

14.07.2003


A University of Minnesota study has confirmed the pivotal role of an enzyme known as JNK2 in the development of nonmelanoma skin cancers. The findings suggest that JNK2 should be evaluated as a target for the prevention and treatment of such cancers. Lead author Zigang Dong, director of the university’s Hormel Institute in Austin, Minn., will present the work at 8:30 a.m. Sunday, July 13, at the American Association for Cancer Research meeting in the Washington Convention Center, 801 Mount Vernon Place NW, Washington, D.C.

Ultraviolet rays from the sun are the major culprit in skin cancer, which accounts for more than half the cancers in the United States. The process of cancer development involves a chain of interactions among biochemicals in the skin, and biochemicals that play key roles in carcinogenesis make potential therapeutic targets. Many human cancers show elevated activity in some form of JNK enzyme, and the enzyme is also activated by sunlight, Dong said.

"Even if one goes into the sun for a few minutes, the activity of JNK in the epidermis rises," said Dong. "If you go out for a few minutes, JNK activity doesn’t stay elevated. But it looks as though if a person gets too much sun exposure, JNK activity becomes permanently elevated and cancers develop. This study indicates that some form of JNK activity is a key step in the process by which nonmelanoma cancers grow."



Working with mice, Dong and his colleagues focused on two enzymes known to be activated by factors that cause cells to divide and that have been considered important in skin cells’ response to UV light. Of the two enzymes, called JNK1 and JNK2, only the latter turned out to play an important role in the development of tumors.

The researchers used two lines of mice that had been rendered enzyme-deficient by inactivation of the gene for either JNK1 or JNK2 in fertilized mouse eggs. When the mice were two months old, the scientists applied a chemical carcinogen to the skin of their backs, followed by five-times-a-week exposure to UVB light, the ultraviolet light that causes skin cancer. At 31 weeks of age, a much smaller percentage of JNK2-deficient mice had tumors (18 percent), compared to control mice (48 percent) or JNK1-lacking mice (50 percent). At 40 weeks of age, the percentage of tumor-bearing JNK2-deficient mice had almost doubled, to 35 percent, while the percentage rose more slowly in control mice (to 56 percent) and JNK1-deficient mice (to 73 percent).

The data suggest that when JNK2 is lacking, skin cells are inhibited, or at least delayed, in their response to UVB light.

"Knocking out the JNK2 enzyme could simply delay the response to ultraviolet light, but if so, it would be significant," Dong said. "If we age enough, every one of us will get cancer. But if we can delay the process, that’s good progress."

The researchers also studied the biochemistry of skin and embryonic cells from the mice. They found that UVB light and a chemical known to promote tumor formation induced biochemical activity associated with cell division and tumor growth in control mice and JNK1-deficient mice, but not in JNK2-deficient mice.


The work was supported by the National Institutes of Health.


Contacts:

Zigang Dong, Hormel Institute director, (507) 437-9600

Deane Morrison, University News Service, (612) 624-2346

Deane Morrison | EurekAlert!
Further information:
http://www.umn.edu/

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>